Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Continuing Operations (2016 - 2026)

Gyre Therapeutics has reported Income from Continuing Operations over the past 16 years, most recently at 22101000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 1247.62% to 22101000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10855000.0 through Dec 2025, down 169.19% year-over-year, with the annual reading at 10855000.0 for FY2025, 169.19% down from the prior year.
  • Income from Continuing Operations was 22101000.0 for Q4 2025 at Gyre Therapeutics, down from 5936000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 51632000.0 in Q2 2022 and troughed at 100977000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 32000.0 (2024), against an average of 8213250.0.
  • Year-over-year, Income from Continuing Operations surged 359.42% in 2022 and then crashed 1247.62% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 20387000.0 in 2021, then tumbled by 36.84% to 27898000.0 in 2022, then crashed by 261.95% to 100977000.0 in 2023, then soared by 98.38% to 1640000.0 in 2024, then crashed by 1247.62% to 22101000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Income from Continuing Operations are 22101000.0 (Q4 2025), 5936000.0 (Q3 2025), and 1576000.0 (Q2 2025).